Valeant is down 13%

Valeant shares dropped by as much as 13% in premarket trading on Monday.

It’s a big day for the pharmaceutical giant. Ten of the company’s executives including CEO Michael Pearson are scheduled to hold a conference call later on Monday to respond to all the news of the past week.

To recap: Short-selling firm Citron Research asked whether Valeant was the next Enron. Citron alleged that the company used fake invoices to stoke its revenues through its relationship with Philidor, a specialty pharmacy.

Valeant issued a statement last week saying that all transactions with its network pharmacies were not included in its consolidated financial statements.

And on Monday morning, the company came out with another release saying that its Audit and Risk Committee and board confirmed “the appropriateness of the company’s related revenue recognition and accounting treatment.”

Valeant shares have fallen nearly 35% over the past week.

NOW WATCH: This animated map shows how humans migrated across the globe

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.